![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: KMT2D |
Gene summary for KMT2D |
![]() |
Gene information | Species | Human | Gene symbol | KMT2D | Gene ID | 8085 |
Gene name | lysine methyltransferase 2D | |
Gene Alias | AAD10 | |
Cytomap | 12q13.12 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O14686 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8085 | KMT2D | NAFLD1 | Human | Liver | NAFLD | 1.71e-02 | 3.79e-01 | -0.04 |
8085 | KMT2D | HCC1_Meng | Human | Liver | HCC | 1.03e-26 | -5.81e-03 | 0.0246 |
8085 | KMT2D | HCC2_Meng | Human | Liver | HCC | 1.88e-03 | 7.37e-03 | 0.0107 |
8085 | KMT2D | HCC2 | Human | Liver | HCC | 4.38e-12 | 2.79e+00 | 0.5341 |
8085 | KMT2D | S014 | Human | Liver | HCC | 5.35e-08 | 4.58e-01 | 0.2254 |
8085 | KMT2D | S015 | Human | Liver | HCC | 8.20e-10 | 5.17e-01 | 0.2375 |
8085 | KMT2D | S016 | Human | Liver | HCC | 7.27e-13 | 5.04e-01 | 0.2243 |
8085 | KMT2D | S027 | Human | Liver | HCC | 2.02e-07 | 6.06e-01 | 0.2446 |
8085 | KMT2D | S028 | Human | Liver | HCC | 1.67e-15 | 6.83e-01 | 0.2503 |
8085 | KMT2D | S029 | Human | Liver | HCC | 2.66e-11 | 5.24e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00485457 | Liver | NAFLD | response to steroid hormone | 75/1882 | 339/18723 | 3.44e-11 | 1.12e-08 | 75 |
GO:00165703 | Liver | NAFLD | histone modification | 90/1882 | 463/18723 | 5.74e-10 | 1.28e-07 | 90 |
GO:00713836 | Liver | NAFLD | cellular response to steroid hormone stimulus | 48/1882 | 204/18723 | 1.50e-08 | 1.83e-06 | 48 |
GO:00305226 | Liver | NAFLD | intracellular receptor signaling pathway | 55/1882 | 265/18723 | 1.39e-07 | 1.03e-05 | 55 |
GO:00160495 | Liver | NAFLD | cell growth | 85/1882 | 482/18723 | 1.75e-07 | 1.25e-05 | 85 |
GO:0018205 | Liver | NAFLD | peptidyl-lysine modification | 65/1882 | 376/18723 | 9.42e-06 | 3.02e-04 | 65 |
GO:00097556 | Liver | NAFLD | hormone-mediated signaling pathway | 39/1882 | 190/18723 | 1.15e-05 | 3.58e-04 | 39 |
GO:00485884 | Liver | NAFLD | developmental cell growth | 45/1882 | 234/18723 | 1.50e-05 | 4.38e-04 | 45 |
GO:00165713 | Liver | NAFLD | histone methylation | 29/1882 | 141/18723 | 1.40e-04 | 2.63e-03 | 29 |
GO:00434016 | Liver | NAFLD | steroid hormone mediated signaling pathway | 28/1882 | 136/18723 | 1.78e-04 | 3.14e-03 | 28 |
GO:00349682 | Liver | NAFLD | histone lysine methylation | 24/1882 | 115/18723 | 4.06e-04 | 6.02e-03 | 24 |
GO:00305185 | Liver | NAFLD | intracellular steroid hormone receptor signaling pathway | 24/1882 | 116/18723 | 4.64e-04 | 6.74e-03 | 24 |
GO:00064793 | Liver | NAFLD | protein methylation | 33/1882 | 181/18723 | 5.36e-04 | 7.35e-03 | 33 |
GO:00082133 | Liver | NAFLD | protein alkylation | 33/1882 | 181/18723 | 5.36e-04 | 7.35e-03 | 33 |
GO:0018023 | Liver | NAFLD | peptidyl-lysine trimethylation | 13/1882 | 50/18723 | 1.04e-03 | 1.22e-02 | 13 |
GO:0018022 | Liver | NAFLD | peptidyl-lysine methylation | 24/1882 | 131/18723 | 2.70e-03 | 2.47e-02 | 24 |
GO:0043414 | Liver | NAFLD | macromolecule methylation | 47/1882 | 316/18723 | 4.08e-03 | 3.41e-02 | 47 |
GO:00331433 | Liver | NAFLD | regulation of intracellular steroid hormone receptor signaling pathway | 15/1882 | 74/18723 | 6.18e-03 | 4.62e-02 | 15 |
GO:00305203 | Liver | NAFLD | intracellular estrogen receptor signaling pathway | 12/1882 | 54/18723 | 6.44e-03 | 4.69e-02 | 12 |
GO:001657021 | Liver | HCC | histone modification | 283/7958 | 463/18723 | 2.68e-16 | 2.33e-14 | 283 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa003108 | Liver | NAFLD | Lysine degradation | 21/1043 | 63/8465 | 1.09e-05 | 3.58e-04 | 2.89e-04 | 21 |
hsa0031011 | Liver | NAFLD | Lysine degradation | 21/1043 | 63/8465 | 1.09e-05 | 3.58e-04 | 2.89e-04 | 21 |
hsa0031041 | Liver | HCC | Lysine degradation | 47/4020 | 63/8465 | 1.02e-05 | 7.58e-05 | 4.22e-05 | 47 |
hsa0031051 | Liver | HCC | Lysine degradation | 47/4020 | 63/8465 | 1.02e-05 | 7.58e-05 | 4.22e-05 | 47 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KMT2D | SNV | Missense_Mutation | c.7982N>A | p.Leu2661His | p.L2661H | O14686 | protein_coding | deleterious(0.01) | probably_damaging(0.921) | TCGA-78-7152-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
KMT2D | SNV | Missense_Mutation | c.13025N>T | p.Gly4342Val | p.G4342V | O14686 | protein_coding | tolerated_low_confidence(0.17) | possibly_damaging(0.497) | TCGA-86-8073-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
KMT2D | SNV | Missense_Mutation | c.9270G>T | p.Glu3090Asp | p.E3090D | O14686 | protein_coding | tolerated(0.08) | possibly_damaging(0.629) | TCGA-86-A4JF-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | unknown | PD | |
KMT2D | SNV | Missense_Mutation | novel | c.8742N>A | p.His2914Gln | p.H2914Q | O14686 | protein_coding | tolerated(0.16) | benign(0.015) | TCGA-91-6836-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KMT2D | SNV | Missense_Mutation | c.784N>T | p.Ala262Ser | p.A262S | O14686 | protein_coding | deleterious(0) | possibly_damaging(0.525) | TCGA-97-7938-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
KMT2D | SNV | Missense_Mutation | c.2605G>A | p.Glu869Lys | p.E869K | O14686 | protein_coding | deleterious_low_confidence(0.02) | benign(0.003) | TCGA-97-A4M0-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
KMT2D | SNV | Missense_Mutation | novel | c.781N>T | p.Thr261Ser | p.T261S | O14686 | protein_coding | deleterious(0.04) | benign(0.118) | TCGA-L9-A444-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KMT2D | SNV | Missense_Mutation | c.12956N>T | p.Arg4319Ile | p.R4319I | O14686 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.648) | TCGA-MP-A4TF-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | navelbine | PD | |
KMT2D | SNV | Missense_Mutation | c.14334A>T | p.Lys4778Asn | p.K4778N | O14686 | protein_coding | tolerated(0.13) | benign(0.006) | TCGA-MP-A4TK-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
KMT2D | SNV | Missense_Mutation | novel | c.5012N>T | p.Ser1671Ile | p.S1671I | O14686 | protein_coding | deleterious(0.01) | possibly_damaging(0.888) | TCGA-NJ-A4YQ-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8085 | KMT2D | METHYL TRANSFERASE, ENZYME, CLINICALLY ACTIONABLE | HDAC INHIBITOR AR-42 | 25273096 |
Page: 1 |